Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: A comparative evaluation

Current Clinical Pharmacology

Volumn 8, Issue 2, 2013, Pages 169-172

  Rosania, Rosa ^a   Giorgio, Floriana ^a   Principi, Mariabeatrice ^b   Amoruso, Annacinzia ^b   Monno, Rosa ^b   Di Leo, Alfredo ^b   Ierardi, Enzo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Antibiotics; Glucose breath test; Lactobacillus casei; Lactulose breath test; Prebiotics; Probiotics; Rifaximin; Rome III criteria; Short chain olygosaccarides; Small intestinal bacterial overgrowth (SIBO)

Indexed keywords

FRUCTOSE OLIGOSACCHARIDE; GLUCOSE; LACTULOSE; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL OVERGROWTH; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FECES COMPOSITION; FEMALE; FOLLOW UP; HUMAN; LACTOBACILLUS CASEI; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; ANTI-BACTERIAL AGENTS; BLIND LOOP SYNDROME; BREATH TESTS; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; INTESTINE, SMALL; LACTOBACILLUS CASEI; LACTULOSE; MALE; MIDDLE AGED; OLIGOSACCHARIDES; PREBIOTICS; PROBIOTICS; QUESTIONNAIRES; RIFAMYCINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876830437     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748847113089990048     Document Type: Article

References (19)

1. Gorbach SL. Intestinal microflora. Gastroenterology 1971; 60(6):1110-29.
2. Grover M, Kanazawa M, Palsson OS, et al. Small intestinalbacterial overgrowth in irritable bowel syndrome: association withcolon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil 2008; 20(9): 998-1008.
3. Lisowska A, Pogorzelski A, Oracz G, et al. Oral antibiotic therapyimproves fat absorption in cystic fibrosis patients with smallintestine bacterial overgrowth. J Cyst Fibros 2011; 10(6): 418-21.
4. Dahlqvist G, Piessevaux H. Irritable bowel syndrome: the role ofthe intestinal microbiota, pathogenesis and therapeutic targets. ActaGastroenterol Belg 2011; 74(3): 375-80.
5. Soifer LO, Peralta D, Dima G, Besasso H. Comparative clinicalefficacy of a probiotic vs. an antibiotic in the treatment of patientswith intestinal bacterial overgrowth and chronic abdominalfunctional distension: a pilot study. Acta Gastroenterol Latinoam2010; 40(4): 323-7.
6. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic reviewof diagnostic tests for small intestinal bacterial overgrowth. Dig DisSci 2008; 53(6): 1443-54.
7. Parodi A, Dulbecco P, Savarino E, et al. Positive glucose breathtesting is more prevalent in patients with IBS-like symptomscompared with controls of similar age and gender distribution. JClin Gastroenterol 2009; 43(10): 962-6.
8. Mínguez Pérez M, Benages Martínez A. The Bristol scale-a usefulsystem to assess stool form? Rev Esp Enferm Dig 2009; 101(5):305-11.
9. Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients 2011; 3(6): 637-82.
10. Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors ofsmall intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 2011; 33(9): 1059-67.
11. Floch MH. Advances in intestinal microecology: the microbiome, prebiotics, and probiotics. Nutr Clin Pract 2012; 27(2): 193-4.
12. Booijink CC, El-Aidy S, Rajili-Stojanovi M, et al. High temporaland inter-individual variation detected in the human ilealmicrobiota. Environ Microbiol 2010; 12(12): 3213-27.
13. Guschin DY, Mobarry BK, Proudnikov D, Stahl DA, Rittmann BE, Mirzabekov AD. Oligonucleotide microchips as genosensors fordeterminative and environmental studies in microbiology. ApplEnviron Microbiol 1997; 63(6): 2397-402.
14. Ahmed S, Macfarlane GT, Fite A, McBain AJ, Gilbert P, Macfarlane S. Mucosa-associated bacterial diversity in relation tohuman terminal ileum and colonic biopsy samples. Appl EnvironMicrobiol 2007; 73(22): 7435-42.
15. Zoetendal EG, Raes J, van den Bogert B, et al. The human smallintestinal microbiota is driven by rapid uptake and conversion ofsimple carbohydrates. ISME J 2012; 6(7): 1415-26.
16. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial:the effects of a trans-galactooligosaccharide prebiotic on faecalmicrobiota and symptoms in irritable bowel syndrome. AlimentPharmacol Ther 2009; 29(5): 508-18.
17. Plöger S, Stumpff F, Penner GB, et al. Microbial butyrate and itsrole for barrier function in the gastrointestinal tract. Ann N Y AcadSci 2012; 1258: 52-9.
18. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota infunctional bowel disorders: a Rome foundation report. Gut 2013;62(1): 159-76.
19. Lamsal BP. Production, health aspects and potential food uses ofdairy prebiotic galactooligosaccharides. J Sci Food Agric 2012;92(10): 2020-8